{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:23:55Z","timestamp":1787840635606,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Acute rheumatic fever is an immunologically delayed autoimmune sequel of throat infection caused by group A streptococcus. The aim of this study was to evaluate endocan levels in patients with acute rheumatic fever and compare with the control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate endocan levels in patients with acute rheumatic fever and compare with the control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Twenty-three children with acute rheumatic fever (11 men, 12 females; mean age 13 \u00b1 2.7 years; range 5 to 15 years) and a healthy control group of 31 children (16 men, 15 females; mean age 13.8 \u00b1 2.4 years; range 5 to 15 years) were recruited. The sedimentation rate, C-reactive protein, antistreptolysin-O titres, and endocan levels were examined in each group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Before anti-inflammatory therapy, endocan levels in the acute rheumatic fever group were not statistically significant to those in the control group, respectively (200.64 ng\/L, 120.71 ng\/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.208). After anti-inflammatory therapy, endocan levels were significantly higher in the acute rheumatic fever group than in the control group, respectively (260.87 ng\/L vs. 120.71 ng\/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). A significant difference was found in endocan levels before and after anti-inflammatory therapy in the group of acute rheumatic fever, respectively (200.64 ng\/L vs. 260.87 ng\/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.033). Endocan levels after anti-inflammatory therapy were statistically higher in the severe carditis group compared to those of the mild carditis group, respectively (344.56 ng\/L vs. 191.01 ng\/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our study showed that serum endocan levels increased during the subacute phase of acute rheumatic fever. We suggest that serum endocan level can be used as a new biomarker to identify the degree of cardiac involvement in acute rheumatic fever.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_783_23","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T14:02:36Z","timestamp":1727704956000},"page":"1051-1056","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Serum Endocan Levels in Children with Acute Rheumatic Fever"],"prefix":"10.4103","volume":"27","author":[{"given":"MT","family":"Do\u011fan","sequence":"first","affiliation":[{"name":"Department of Pediatric Cardiology, Selcuk University, MD, Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Can","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Konya City Hospital, Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Alp","sequence":"additional","affiliation":[{"name":"Department of Pediatric Cardiology, Karamano\u011flu Mehmet Bey University, Karaman, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Aygune\u015f","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Konya Training and Research Hospital, MD, Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"R1-20250306","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1017\/S0950268800003514","article-title":"Cumulative incidence of rheumatic fever in an endemic region: A guide to the susceptibility of the population?","volume":"124","author":"Carapetis","year":"2000","journal-title":"Epidemiol Infect"},{"key":"R2-20250306","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMp078039","article-title":"Rheumatic heart disease in developing countries","volume":"357","author":"Carapetis","year":"2007","journal-title":"N Engl J Med"},{"key":"R3-20250306","first-page":"25","article-title":"Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy","volume":"1765","author":"Sarrazin","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"R4-20250306","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.4049\/jimmunol.167.6.3099","article-title":"Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a\/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1","volume":"167","author":"B\u00e8chard","year":"2001","journal-title":"J Immunol"},{"key":"R5-20250306","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7754\/Clin.Lab.2013.130333","article-title":"Serum endocan levels are increased in patients with inflammatory bowel disease","volume":"60","author":"Voiosu","year":"2014","journal-title":"Clin Lab"},{"key":"R6-20250306","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jaad.2013.09.013","article-title":"Serum endocan levels as a marker of disease activity in patients with Beh\u00e7et disease","volume":"70","author":"Balta","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R7-20250306","doi-asserted-by":"crossref","first-page":"788864","DOI":"10.3389\/fped.2021.788864","article-title":"Endocan: A novel marker for colchicine resistance in familial mediterranean fever patients?","volume":"9","author":"Omma","year":"2021","journal-title":"Front Pediatr"},{"key":"R8-20250306","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5606\/ArchRheumatol.2018.6528","article-title":"The assessment of serum endocan levels in children with juvenile idiopathic arthritis","volume":"33","author":"Y\u0131maz","year":"2018","journal-title":"Arch Rheumatol"},{"key":"R9-20250306","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1161\/CIR.0000000000000205","article-title":"Revision of the Jones criteria for the diagnosis of the rheumatic fever in the era of Doppler echocardiography: A scientific statement of the American Heart Association","volume":"131","author":"Gewitz","year":"2015","journal-title":"Circulation"},{"key":"R11-20250306","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/01.CIR.58.6.1072","article-title":"Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardio-graphic measurements","volume":"58","author":"Sahn","year":"1978","journal-title":"Circulation"},{"key":"R12-20250306","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0022-5223(19)38504-6","article-title":"Intraoperative color flow mapping by real-time two-dimensional Doppler echocardiography for evaluation of valvular and congenital heart disease and vascular disease","volume":"90","author":"Takamoto","year":"1985","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R13-20250306","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/0002-9149(93)91018-D","article-title":"Semiquantitative assess- ment of mitral regurgitation by Doppler color flow ima- ging in patients aged <20 years","volume":"71","author":"Wu","year":"1993","journal-title":"Am J Cardiol"},{"key":"R14-20250306","doi-asserted-by":"crossref","first-page":"20458","DOI":"10.1074\/jbc.271.34.20458","article-title":"ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines","volume":"271","author":"Lassalle","year":"1996","journal-title":"J Biol Chem"},{"key":"R15-20250306","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/ki.2014.227","article-title":"Plasma endocanlevels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease","volume":"86","author":"Yilmaz","year":"2014","journal-title":"Kidney Int"},{"key":"R16-20250306","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.atherosclerosis.2015.09.030","article-title":"Endocan: A novel inflammatory indicator in cardiovascular disease?","volume":"243","author":"Balta","year":"2015","journal-title":"Atherosclerosis"},{"key":"R17-20250306","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1177\/0003319713513492","article-title":"Endocan-a novel inflammatory indicator in newly diagnosed patients with hypertension: A pilot study","volume":"65","author":"Balta","year":"2014","journal-title":"Angiology"},{"key":"R18-20250306","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0090-1229(89)90174-8","article-title":"Identification of mononuclear cells and T cell subsets in rheumatic valvulitis","volume":"52","author":"Kemeny","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"R19-20250306","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1161\/01.CIR.88.5.2198","article-title":"Does endomyocardial biopsy aid in the diagnosis of active rheumatic carditis?","volume":"88","author":"Narula","year":"1993","journal-title":"Circulation"},{"key":"R20-20250306","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0022-2828(90)91008-U","article-title":"Role of oxygen free radicals generated by blood monocytes and neutrophils in the pathogenesis of rheumatic fever and rheumatic heart disease","volume":"22","author":"Kumar","year":"1990","journal-title":"J Mol Cell Cardiol"},{"key":"R21-20250306","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1017\/S1047951101000300","article-title":"Oxygen free radicals in children with acute rheumatic fever","volume":"11","author":"Oran","year":"2001","journal-title":"Cardiol Young"},{"key":"R22-20250306","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s004310050545","article-title":"Cytokines in acute rheumatic fever","volume":"156","author":"Yegin","year":"1997","journal-title":"Eur J Pediatr"},{"key":"R23-20250306","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/03009749509095185","article-title":"Plasma interleukin-7 (IL-7) and IL-8 concentrations in acute rheumatic fever and chronic rheumatic heart disease","volume":"24","author":"Kutukculer","year":"1995","journal-title":"Scand J Rheumatol"},{"key":"R24-20250306","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/clin.1995.1140","article-title":"Lymphocyte subsets and plasma IL-1 alpha, IL-2, and TNF-alpha concentrations in acute rheumatic fever and chronic rheumatic heart disease","volume":"77","author":"Narin","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"R25-20250306","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2143\/AC.65.1.2045889","article-title":"Investigation of oxidant and antioxidant pathway changes in acute rheumatic fever","volume":"65","author":"Uner","year":"2010","journal-title":"Acta Cardiol"},{"key":"R26-20250306","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijcard.2005.04.030","article-title":"Further evidence of inflammation in chronic rheumatic valve disease (CRVD): High levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP)","volume":"109","author":"Chiu-Braga","year":"2006","journal-title":"Int J Cardiol"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_783_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:26:15Z","timestamp":1787837175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_783_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_783_23","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"2023-11-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}